Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Q2 2025 Earnings Call Transcript August 15, 2025 Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity ...

A new cancer drug that can be injected directly into tumors eradicated breast cancer and melanoma metastases in a handful of ...

BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) reported second quarter 2025 results, producing license revenues of $304,000. Following the transition of commercialization ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Cancer is not solely a disease of uncontrolled cell proliferation, but also one of immune system failure. The concept of cancer immunoediting—comprising the ...

HHS' decision "could stagnate research that has the potential to save millions of lives," writes Simon Williams.

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.